Menu Back to Canadian-Pharmacovigilance-and-Risk-Management-Strategies-Conference


DIA’s Canadian Pharmacovigilance and Risk Management Strategies Conference is the premier place to hear from expert pharmaceutical, biotechnology, and regulatory personnel about Global Regulatory Guidance Document updates (pharmacovigilance, risk management, and drug safety), gain new perspectives from the Inspectorate, and discuss patient support programs and PV responsibilities. Join in on an exclusive session with the Canadian regulator, touching on a host of current topics including the management of Canada Vigilance Adverse Reaction Online Database duplicate safety reports.

On-Demand Complimentary Webinar

Plain Language Labeling for Over-the-Counter Drugs: Implementing Health Canada’s Guidance for Industry
This webinar will review Health Canada’s requirements for Plain Language Labeling for over-the-counter medicines. Presenters will walk through key recently finalized and revised guidance documents to help industry comply with these requirements and identify strategies to help industry add Drug Facts Tables to packaging while minimizing the need for packaging increases. Register today!

DIA's Canadian Health Care Content Roundup

NEW! This year DIA's Canadian Pharmacovigilance and Risk Management Conference will be co-located with the DIA Canadian Annual Meeting. Maximize your education and time by attending both!
While our conference is currently in development, check out last year’s program to see what’s in store!
View Program.


Want to learn more about Canadian Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!


Learn more

Who should attend?

Professionals involved in:

  • Advertising and Promotion
  • Biotechnology
  • Clinical Data Management/eClinical
  • CMC
  • Combination Products
  • Clinical Safety and Pharmacovigilance
  • Clinical Research
  • Medical Devices and Diagnostics
  • Pharmacology
  • Regulatory Affairs

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Describe the current Canadian regulatory framework for pharmacovigilance
  • Examine current Pharmacovigilance issues facing Marketing Authorization Holders in Canada
  • Discuss proposed changes to Vanessa’s Law
  • Identify strategies for implementing benefit-risk analyses and risk management plans

Program Committee

  • Rita  Cassola, RPh
    Rita Cassola, RPh Executive Director PV
    Certus PV Services Inc, Canada
  • Marcia  Bailey, BSN, MHS, RN
    Marcia Bailey, BSN, MHS, RN Safety Evaluation & Risk Management Scientific Director
    GSK, Canada
  • Colin  D'Cunha, MD, MHS, FRCPC
    Colin D'Cunha, MD, MHS, FRCPC Director, Global Medical Affairs
    Apotex Inc., Canada
  • Ljubica  Ivanisevic, PhD
    Ljubica Ivanisevic, PhD Scientific Evaluator
    Health Canada, Canada
  • Marc  Poitras, PhD, MBA
    Marc Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada
Load More

Contact us

Digital Learning Catalog

DIA Learning: eLearning Soultions